Otros idiomas Travere Therapeutics, Inc.

Acciones

TVTX

US89422G1076

Biotecnología e investigación médica

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 12/06/2026			Variación 5 días	Varia. 1 de enero.
52,04 ^USD	+6,40 %		+13,60 %	+36,19 %

08/06	Travere Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 11:20 AM
04/06	Travere Therapeutics, Inc. presenta datos de la extensión abierta a largo plazo del estudio de fase 3 DUPLEX sobre Filspari en la glomeruloesclerosis focal y segmentaria	CI

Otros idiomas

11/06	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06	Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
04/06	Travere Therapeutics, Inc. Presents Long-Term Open-Label Extension Data from the Phase 3 Duplex Study of Filspari in Focal Segmental Glomerulosclerosis
03/06	Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
02/06	Everest Medicines Unit Grants Kidney Disease Development, Commercialization License
02/06	Travere licenses Everest's kidney disease drug in deal worth up to $1.14 billion
02/06	Travere Therapeutics Signs Deal to License Potential Kidney Disease Drug From Everest Medicines
02/06	Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
27/05	Travere Therapeutics Receives USPTO Notice of Allowance for FILSPARI Patent in IgA Nephropathy
27/05	Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
27/05	Travere Therapeutics Receives Notice of Allowance for U.S. Patent Application Directed to Certain Methods of Using FILSPARI in IgA Nephropathy
12/05	Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
12/05	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/05	Travere Therapeutics to Participate at Upcoming Investor Conferences
07/05	Travere Therapeutics Prices Upsized $475 Million Debt Offering
07/05	Travere Therapeutics Insider Sold Shares Worth $988,875, According to a Recent SEC Filing
07/05	Travere Therapeutics Insider Sold Shares Worth $1,015,086, According to a Recent SEC Filing
07/05	Travere Therapeutics Insider Sold Shares Worth $1,092,657, According to a Recent SEC Filing
07/05	Travere Therapeutics Insider Sold Shares Worth $360,000, According to a Recent SEC Filing
07/05	Travere prices upsized $475.0 million convertible senior notes offering to refinance 2029 convertible notes
07/05	Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
05/05	Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
05/05	Travere Therapeutics : Investor Fact Sheet
04/05	Travere Therapeutics Q1 Swings to Profit, Revenue Rises
04/05	Travere Therapeutics : Q1 2026 Earnings Presentation